6 known cases. View patent page →
Padagis petitioned for inter partes review of the '414 patent, challenging claims 1–18 as obvious over Gwozdz and Meezan. Trial was instituted, and the case remains pending with no final written decision.
ANDA/Hatch-Waxman litigation over Padagis ANDA No. 219320 for generic diazepam nasal spray. It is the lead consolidated action and asserts the '414 patent along with related family patents. Trial is scheduled as a bench trial beginning March 1, 2027.
ANDA case against Amneal concerning Amneal's ANDA No. 219109 products. The complaint analysis identifies the '414 patent and related family members such as the '852 and '061 patents, and the case is consolidated with the lead Delaware action.
Named as a related consolidated ANDA action under lead case 1:24-cv-00562-MN. The narrative groups these dockets in the same patent family and as likely asserting the '414 patent, but provides no separate patent list for this docket.
ANDA case against Strides relating to ANDA No. 221329 and identified as a related action consolidated under lead case 1:24-cv-00562-MN. The Strides complaint expressly asserts the '414 patent among the asserted patents.
ANDA case against Strides over diazepam nasal spray under Strides ANDA No. 221329; coordinated with the consolidated VALTOCO ANDA actions.